NCT01692678View on ClinicalTrials.gov

A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma

PHASE3CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 7, 2012

Primary Completion Date

October 11, 2016

Study Completion Date

October 11, 2016

Conditions
Advanced or Metastatic Liposarcoma or Leiomyosarcoma
Interventions
DRUG

Trabectedin

Type=exact number, unit=mg/m2, number=1.5, 1.2 or 1.0, form=solution, route=intravenous infusion. Trabectedin will be administered on Day 1 of each 21-day treatment cycle.

DRUG

Dacarbazine

Type=exact number, unit=g/m2, number=1, form=solution, route=intravenous infusion. Dacarbazine will be administered on Day 1 of each 21-day treatment cycle.

Trial Locations (2)

Unknown

Beijing

Shanghai

All Listed Sponsors
lead

Xian-Janssen Pharmaceutical Ltd.

INDUSTRY

NCT01692678 - A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma | Biotech Hunter | Biotech Hunter